Pulmonary Arterial Hypertension: Meeting Critical Care Needs

Note: If you attended the live CE activity AND received CE credit (i.e. a pharmacist CE statement of credit with ACPE UAN 0221-0000-20-297-L01-P), you are NOT allowed to also receive credit for this home-study on-demand web activity.

Activity Description

This activity will focus on foundational PAH knowledge including signs and symptoms, etiology, treatment, and patient education. The format will utilize a patient case presentation to highlight therapeutic approaches to manage PAH with a focus on critical care management. The session will cover insights into PAH pathophysiology, PAH therapies and the most recent data surrounding their uses, clinical guidelines, and optimal management during transitions of care. Opportunities for nurses to use patient-centered care approaches during transitions of care including cost management, anticipated side effects, the importance of adherence will also be discussed.

Learning Objectives

The target audience for this activity includes nurses and pharmacists. At the completion of this activity, the participant will be able to:

  • Discuss the revised definition, classification, and diagnostic algorithm for pulmonary arterial hypertension (PAH).
  • Discuss the revised treatment algorithm for PAH and the 3 treatment pathways.
  • Outline nursing methods to improve adherence in PAH through careful medication titration and side effect management.


Martha Kingman, DNP, FNP-C
Nurse Practitioner
Pulmonary Hypertension Comprehensive Care Center
University of Texas Southwestern Medical Center at Dallas

CE Accreditation

Release Date: 7-16-2020
Expiration Date: 8-5-2021


ProCE, Inc. is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. ACPE Universal Activity Number 0221-0000-20-297-H01-P has been assigned to this home study knowledge-based activity. This activity is approved for 1.0 contact hours (0.1 CEU) in states that recognize ACPE providers. The activity is provided at no cost to participants. Completion of the evaluation and the post-test with a score of 70% or higher are required to receive CE credit. No partial credit will be given. Statements of completion will be issued online at www.ProCE.com, and proof of completion will be posted in NABP CPE Monitor profiles.

Nurses(Pharmacology Credit)

This CE activity is jointly provided by ProCE, Inc. and Wild Iris Medical Education, Inc. This activity provides 1.0 contact hour of nurse CE credit.

Wild Iris Medical Education, Inc. is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center's Commission on Accreditation.


It is the policy of ProCE, Inc. to ensure balance, independence, objectivity and scientific rigor in all of its continuing education activities. Faculty must disclose to participants any significant financial interest or affiliation with companies that manufacture or market products discussed during their presentation. Martha Kingman is an advisory Board Member for Actelion, Bayer, United Therapeutics, and Liquidia and a consultant for Actelion, Bayer, and Liquidia.


This activity is supported by an educational grant from Actelion Pharmaceuticals US, Inc.


The material presented in this CE activity does not reflect the views of ProCE, Inc. or the commercial sponsor. These materials may discuss uses and dosages for therapeutic products, processes, procedures and inferred diagnoses that have not been approved by the United States Food and Drug Administration. A qualified health care professional should be consulted before using any therapeutic product discussed. All readers and continuing education participants should verify all information and data before treating patients or employing any therapies described in this continuing education activity.